US 2026/0097038 A1 · COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH

Abstract

The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a mTOR inhibitor and a KRas G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

Claims18

Dependent claims

A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a mTOR inhibitor and a KRas G12C inhibitor of formula:

or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application

19/406,155Filed 2 Dec 2025

Priority

10 Sep 2018

Published

9 Apr 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61K 31/436
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a six-membered ring having oxygen as a ring…
A61K 31/4523
Non condensed piperidines, e.g. piperocaine: containing further heterocyclic ring systems

COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH

Life of this patent

COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH

Life of this patent

Abstract

Claims18